“Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s692. https://doi.org/10.25251/w6str133.